Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ARWR
ARWR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARWR News
Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress
4d ago
Newsfilter
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
May 12 2026
PRnewswire
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
May 12 2026
Newsfilter
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
May 08 2026
seekingalpha
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
May 04 2026
Newsfilter
Latest Wall Street Rating Updates
May 01 2026
CNBC
REDEMPLO Approved in Australia for FCS Treatment
May 01 2026
Newsfilter
Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
Apr 24 2026
stocktwits
US Stocks Rise on Strong Retail Sales and Earnings Reports
Apr 21 2026
NASDAQ.COM
U.S. Stocks Mixed as Oil Prices Rebound
Apr 21 2026
NASDAQ.COM
US Stocks Close Lower as Oil Prices Rebound Impact Market
Apr 21 2026
NASDAQ.COM
Morgan Stanley Upgrades Arrowhead to Overweight with $100 Target
Apr 21 2026
seekingalpha
Arrowhead Pharmaceuticals Stock Outlook Optimistic
Apr 21 2026
CNBC
Latest Wall Street Ratings Overview
Apr 21 2026
CNBC
Arrowhead's Plozasiran Significantly Reduces TG Levels in Hypertriglyceridemia Patients
Mar 28 2026
Newsfilter
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
Mar 26 2026
Newsfilter
Show More News
